DNCA

DNCA is a neutral lipid that has been used in the generation of lipid nanoparticles (LNPs). Intravenous administration of LNPs containing DNCA and encapsulating siRNA targeting BRAF containing a valine-to-glutamate substitution at position 600 (BRAFV600E) reduce tumor BRAFV600E expression and tumor weight and volume without reducing animal weight in an A375 melanoma mouse xenograft model. Intratumoral administration of LNPs containing DNCA and encapsulating cyclic di-GMP (Cay-17144) decreases tumor volume, increase survival, and increase the ratio of tumor-associated cytotoxic/exhausted CD4+ and CD8+ T cells in an EO771 murine model of primary breast cancer with tumor rechallenge.Formal Name: 4-amino-N-[2,3-bis[(9Z)-9-octadecen-1-yloxy]propyl]-2-oxo-1(2H)-pyrimidineacetamide. CAS Number: 2226561-66-4. Molecular Formula: C45H82N4O4. Formula Weight: 743.2. Purity: >95%. Formulation: (Request formulation change), A solution in ethanol. Solubility: Ethanol: 5 mg/ml. SMILES: NC1=NC(N(CC(NCC(COCCCCCCCC/C=C\CCCCCCCC)OCCCCCCCC/C=C\CCCCCCCC)=O)C=C1)=O. InChi Code: InChI=1S/C45H82N4O4/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-37-52-41-42(39-47-44(50)40-49-36-35-43(46)48-45(49)51)53-38-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,35-36,42H,3-16,21-34,37-41H2,1-2H3,(H,47,50)(H2,46,48,51)/b19-17-,20-18-. InChi Key: YFNQKYRJAJXRSL-CLFAGFIQSA-N.